Astragaloside IV Mitigated Diabetic Nephropathy by Restructuring Intestinal Microflora and Ferroptosis

To investigate the underlying mechanism of Astragaloside IV (AS-IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and intestinal mucosal barrier. Genetically db/db mice are used to establish DN mouse model to monitor the therapeutic effects of AS-IV and fecal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular nutrition & food research Jg. 68; H. 6; S. e2300734
Hauptverfasser: Lyu, Xin, Zhang, Ting‐ting, Ye, Zhen, Chen, Ce
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Germany Wiley Subscription Services, Inc 01.03.2024
Schlagworte:
Diabetes
Diabetes mellitus
Diabetic nephropathy
Digestive system
Dysbacteriosis
Ecological effects
Fecal microflora
Ferroptosis
Gastrointestinal tract
Gut microbiota
Intestinal microflora
Intestine
Microbiomes
Microbiota
Microorganisms
Mucosa
Nephropathy
Permeability
Renal function
Transplantation
intestinal microbiota
ferroptosis
Astragaloside IV
gut-renal axis
diabetic nephropathy
ISSN:1613-4125, 1613-4133, 1613-4133
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract To investigate the underlying mechanism of Astragaloside IV (AS-IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and intestinal mucosal barrier. Genetically db/db mice are used to establish DN mouse model to monitor the therapeutic effects of AS-IV and fecal microbiota transplantation (FMT) against DN. Supplementation with AS-IV dramatically attenuates several clinical indicators of DN in db/db mice. In addition, AS-IV markedly improves intestinal barrier function, modifies intestinal permeability, and reduces inflammation. Moreover, AS-IV treatment remarkably improves intestinal dysbiosis in db/db mice, characterized by an elevated abundance of Akkermansia, Ligilactobacillus, and Lactobacillus, indicating the fundamental role of the microbiome in DN progression. Furthermore, FMT derived from AS-IV-treated db/db mice is potentially efficient in antagonizing renal dysfunction, rebalancing gut microbiota, and improving intestinal permeability in recipient db/db mice. AS-IV-enriched Akkermansia muciniphila dramatically alleviates DN and intestinal mucosal barrier dysfunction in db/db mice. Intriguingly, AS-IV intervention dramatically diminishes ferroptosis in the kidney and colon tissues. CONCLUSION : Intestinal microbiome alterations and ferroptosis modulation by AS-IV may play instrumental roles in this mechanism, providing compelling evidence for the role of the gut-renal axis in DN.
AbstractList To investigate the underlying mechanism of Astragaloside IV (AS-IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and intestinal mucosal barrier. Genetically db/db mice are used to establish DN mouse model to monitor the therapeutic effects of AS-IV and fecal microbiota transplantation (FMT) against DN. Supplementation with AS-IV dramatically attenuates several clinical indicators of DN in db/db mice. In addition, AS-IV markedly improves intestinal barrier function, modifies intestinal permeability, and reduces inflammation. Moreover, AS-IV treatment remarkably improves intestinal dysbiosis in db/db mice, characterized by an elevated abundance of Akkermansia, Ligilactobacillus, and Lactobacillus, indicating the fundamental role of the microbiome in DN progression. Furthermore, FMT derived from AS-IV-treated db/db mice is potentially efficient in antagonizing renal dysfunction, rebalancing gut microbiota, and improving intestinal permeability in recipient db/db mice. AS-IV-enriched Akkermansia muciniphila dramatically alleviates DN and intestinal mucosal barrier dysfunction in db/db mice. Intriguingly, AS-IV intervention dramatically diminishes ferroptosis in the kidney and colon tissues. CONCLUSION : Intestinal microbiome alterations and ferroptosis modulation by AS-IV may play instrumental roles in this mechanism, providing compelling evidence for the role of the gut-renal axis in DN.
ScopeTo investigate the underlying mechanism of Astragaloside IV (AS‐IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and intestinal mucosal barrier.Methods and resultsGenetically db/db mice are used to establish DN mouse model to monitor the therapeutic effects of AS‐IV and fecal microbiota transplantation (FMT) against DN. Supplementation with AS‐IV dramatically attenuates several clinical indicators of DN in db/db mice. In addition, AS‐IV markedly improves intestinal barrier function, modifies intestinal permeability, and reduces inflammation. Moreover, AS‐IV treatment remarkably improves intestinal dysbiosis in db/db mice, characterized by an elevated abundance of Akkermansia, Ligilactobacillus, and Lactobacillus, indicating the fundamental role of the microbiome in DN progression. Furthermore, FMT derived from AS‐IV‐treated db/db mice is potentially efficient in antagonizing renal dysfunction, rebalancing gut microbiota, and improving intestinal permeability in recipient db/db mice. AS‐IV‐enriched Akkermansia muciniphila dramatically alleviates DN and intestinal mucosal barrier dysfunction in db/db mice. Intriguingly, AS‐IV intervention dramatically diminishes ferroptosis in the kidney and colon tissues.Conclusion Intestinal microbiome alterations and ferroptosis modulation by AS‐IV may play instrumental roles in this mechanism, providing compelling evidence for the role of the gut‐renal axis in DN.
To investigate the underlying mechanism of Astragaloside IV (AS-IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and intestinal mucosal barrier.SCOPETo investigate the underlying mechanism of Astragaloside IV (AS-IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and intestinal mucosal barrier.Genetically db/db mice are used to establish DN mouse model to monitor the therapeutic effects of AS-IV and fecal microbiota transplantation (FMT) against DN. Supplementation with AS-IV dramatically attenuates several clinical indicators of DN in db/db mice. In addition, AS-IV markedly improves intestinal barrier function, modifies intestinal permeability, and reduces inflammation. Moreover, AS-IV treatment remarkably improves intestinal dysbiosis in db/db mice, characterized by an elevated abundance of Akkermansia, Ligilactobacillus, and Lactobacillus, indicating the fundamental role of the microbiome in DN progression. Furthermore, FMT derived from AS-IV-treated db/db mice is potentially efficient in antagonizing renal dysfunction, rebalancing gut microbiota, and improving intestinal permeability in recipient db/db mice. AS-IV-enriched Akkermansia muciniphila dramatically alleviates DN and intestinal mucosal barrier dysfunction in db/db mice. Intriguingly, AS-IV intervention dramatically diminishes ferroptosis in the kidney and colon tissues. CONCLUSION : Intestinal microbiome alterations and ferroptosis modulation by AS-IV may play instrumental roles in this mechanism, providing compelling evidence for the role of the gut-renal axis in DN.METHODS AND RESULTSGenetically db/db mice are used to establish DN mouse model to monitor the therapeutic effects of AS-IV and fecal microbiota transplantation (FMT) against DN. Supplementation with AS-IV dramatically attenuates several clinical indicators of DN in db/db mice. In addition, AS-IV markedly improves intestinal barrier function, modifies intestinal permeability, and reduces inflammation. Moreover, AS-IV treatment remarkably improves intestinal dysbiosis in db/db mice, characterized by an elevated abundance of Akkermansia, Ligilactobacillus, and Lactobacillus, indicating the fundamental role of the microbiome in DN progression. Furthermore, FMT derived from AS-IV-treated db/db mice is potentially efficient in antagonizing renal dysfunction, rebalancing gut microbiota, and improving intestinal permeability in recipient db/db mice. AS-IV-enriched Akkermansia muciniphila dramatically alleviates DN and intestinal mucosal barrier dysfunction in db/db mice. Intriguingly, AS-IV intervention dramatically diminishes ferroptosis in the kidney and colon tissues. CONCLUSION : Intestinal microbiome alterations and ferroptosis modulation by AS-IV may play instrumental roles in this mechanism, providing compelling evidence for the role of the gut-renal axis in DN.
Author Zhang, Ting‐ting
Chen, Ce
Ye, Zhen
Lyu, Xin
Author_xml – sequence: 1
  givenname: Xin
  surname: Lyu
  fullname: Lyu, Xin
  organization: Department of Endocrinology Suqian First Hospital Suqian 223899 China
– sequence: 2
  givenname: Ting‐ting
  surname: Zhang
  fullname: Zhang, Ting‐ting
  organization: Department of Nephrology Suqian First Hospital Suqian 223899 China
– sequence: 3
  givenname: Zhen
  surname: Ye
  fullname: Ye, Zhen
  organization: Department of Pharmacy Suqian First Hospital Suqian 223899 China
– sequence: 4
  givenname: Ce
  orcidid: 0000-0002-2307-4673
  surname: Chen
  fullname: Chen, Ce
  organization: Key Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Histology and Embryology, School of Medicine Southeast University Nanjing 210009 China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38389170$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1PGzEQhq0KVAjttcfKEpdeEsbr9X4cERSIxIdUtb2uvN5xMNrYwfYe8u8ZFMgBiZPH0vNYfuedsQMfPDL2Q8BCABRna2_jooBCAtSy_MKORSXkvBRSHuznQh2xWUpPAFIUpfzKjmQjm1bUcMzsecpRr_QYkhuQL__zO5fdSmcc-KXTPWZn-D1uHmPY6Py45f2W_0FyJpOn6PyKL32mu_N6JNXEYMcQNdd-4FcYycr0cvrGDq0eE35_O0_Yv6vffy9u5rcP18uL89u5kYXMc1sZ1agGUQ2tkTRAD73qRT1ULVpsVNXbHmsYLMW1ojVKS0SEVpmyHSj0Cfu1e3cTw_NE_-rWLhkcR-0xTKmTtIJKNVA3hJ5-QJ_CFCnGjgJooWyJ-vlGTf0ah24T3VrHbfe-QQIWO4CipxTR7hEB3WtF3WtF3b4iEsoPgnFZZxc8FeHGz7QXuV2WOA
CitedBy_id crossref_primary_10_1016_j_jep_2024_118517
crossref_primary_10_1002_cbf_70067
crossref_primary_10_3389_fphar_2025_1518481
crossref_primary_10_1021_acs_jafc_5c00130
crossref_primary_10_1186_s12916_025_04203_x
crossref_primary_10_1016_j_jep_2025_119579
crossref_primary_10_1016_j_phymed_2025_156643
crossref_primary_10_1016_j_intimp_2024_112794
crossref_primary_10_1142_S0192415X25500405
crossref_primary_10_2147_DDDT_S520323
crossref_primary_10_1016_j_biopha_2024_117008
crossref_primary_10_1111_1753_0407_70068
crossref_primary_10_1111_dme_70087
crossref_primary_10_1007_s00210_024_03373_4
crossref_primary_10_1186_s13020_024_01007_8
crossref_primary_10_3389_fmed_2025_1628722
crossref_primary_10_2147_DMSO_S526076
Cites_doi 10.2337/dc09-0467
10.1016/j.ejphar.2020.173574
10.3389/fendo.2022.1103972
10.1016/j.phrs.2022.106161
10.1007/978-94-017-8841-0_5
10.1038/s41419-021-03452-x
10.2147/IJNRD.S40172
10.1016/j.biopha.2018.10.041
10.1016/j.bbi.2018.02.005
10.1038/nrneph.2015.175
10.1016/j.cell.2012.03.042
10.1038/s41401-018-0029-3
10.1007/s12275-018-8327-5
10.3390/ijms23073842
10.1007/s40620-017-0432-8
10.1007/s00424-020-02352-x
10.1038/s41467-019-09735-4
10.3109/15376516.2012.730558
10.1016/j.tem.2016.07.002
10.3390/nu14163384
10.2337/diabetes.54.7.2206
10.2174/157339908783502361
10.1152/ajprenal.00184.2019
10.1038/s41581-018-0018-2
10.1038/ncpendmet0894
10.1016/j.bbi.2017.06.018
10.1016/j.molmet.2022.101470
10.1007/s12020-021-02721-1
10.3748/wjg.v26.i18.2187
10.1007/s12011-014-0021-9
10.1111/fcp.12232
ContentType Journal Article
Copyright 2024 Wiley-VCH GmbH.
2024 Wiley‐VCH GmbH
2024 Wiley‐VCH GmbH.
Copyright_xml – notice: 2024 Wiley-VCH GmbH.
– notice: 2024 Wiley‐VCH GmbH
– notice: 2024 Wiley‐VCH GmbH.
DBID AAYXX
CITATION
NPM
7QO
7QP
7T5
7T7
7TK
8FD
C1K
FR3
H94
K9.
NAPCQ
P64
7X8
DOI 10.1002/mnfr.202300734
DatabaseName CrossRef
PubMed
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Nursing & Allied Health Premium
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed
Nursing & Allied Health Premium
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Diet & Clinical Nutrition
EISSN 1613-4133
ExternalDocumentID 38389170
10_1002_mnfr_202300734
Genre Journal Article
GrantInformation_xml – fundername: Jiangsu Provincial Pharmaceutical Society-Tianqing Hospital Pharmacy Fund
  grantid: Q202147
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OC
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAFWJ
AAHBH
AAHQN
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAYXX
AAZKR
ABCUV
ABIJN
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCZN
ACGFS
ACIWK
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIDQK
AIDYY
AITYG
AIURR
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
C45
CITATION
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O8X
O9-
OIG
OVD
P2W
P2X
P4D
Q.N
Q11
QB0
QRW
R.K
ROL
RX1
RYL
SUPJJ
SV3
TEORI
UB1
V8K
W8V
W99
WBKPD
WIH
WIK
WJL
WNSPC
WOHZO
WXSBR
WYISQ
XG1
XV2
Y6R
~IA
~KM
~WT
NPM
7QO
7QP
7T5
7T7
7TK
8FD
C1K
FR3
H94
K9.
NAPCQ
P64
7X8
ID FETCH-LOGICAL-c323t-f6c5858ee5d9c358e0b0b5b17d69efe856bfbe70df007f19c5a3eee095c49d133
ISICitedReferencesCount 23
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001169619900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1613-4125
1613-4133
IngestDate Thu Oct 02 14:39:52 EDT 2025
Tue Oct 07 06:48:46 EDT 2025
Mon Jul 21 05:51:05 EDT 2025
Sat Nov 29 06:11:03 EST 2025
Tue Nov 18 20:36:48 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords intestinal microbiota
ferroptosis
Astragaloside IV
gut-renal axis
diabetic nephropathy
Language English
License 2024 Wiley-VCH GmbH.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c323t-f6c5858ee5d9c358e0b0b5b17d69efe856bfbe70df007f19c5a3eee095c49d133
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2307-4673
PMID 38389170
PQID 3031009049
PQPubID 2045123
ParticipantIDs proquest_miscellaneous_3031658078
proquest_journals_3031009049
pubmed_primary_38389170
crossref_primary_10_1002_mnfr_202300734
crossref_citationtrail_10_1002_mnfr_202300734
PublicationCentury 2000
PublicationDate 2024-03-01
PublicationDateYYYYMMDD 2024-03-01
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Hoboken
PublicationTitle Molecular nutrition & food research
PublicationTitleAlternate Mol Nutr Food Res
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_1_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – ident: e_1_2_10_24_1
  doi: 10.2337/dc09-0467
– ident: e_1_2_10_8_1
  doi: 10.1016/j.ejphar.2020.173574
– ident: e_1_2_10_29_1
  doi: 10.3389/fendo.2022.1103972
– ident: e_1_2_10_2_1
– ident: e_1_2_10_15_1
  doi: 10.1016/j.phrs.2022.106161
– ident: e_1_2_10_31_1
  doi: 10.1007/978-94-017-8841-0_5
– ident: e_1_2_10_10_1
  doi: 10.1038/s41419-021-03452-x
– ident: e_1_2_10_3_1
  doi: 10.2147/IJNRD.S40172
– ident: e_1_2_10_13_1
  doi: 10.1016/j.biopha.2018.10.041
– ident: e_1_2_10_17_1
  doi: 10.1016/j.bbi.2018.02.005
– ident: e_1_2_10_25_1
  doi: 10.1038/nrneph.2015.175
– ident: e_1_2_10_7_1
  doi: 10.1016/j.cell.2012.03.042
– ident: e_1_2_10_18_1
  doi: 10.1038/s41419-021-03452-x
– ident: e_1_2_10_21_1
  doi: 10.1038/s41401-018-0029-3
– ident: e_1_2_10_14_1
  doi: 10.1007/s12275-018-8327-5
– ident: e_1_2_10_28_1
  doi: 10.3390/ijms23073842
– ident: e_1_2_10_26_1
  doi: 10.1007/s40620-017-0432-8
– ident: e_1_2_10_5_1
  doi: 10.1007/s00424-020-02352-x
– ident: e_1_2_10_19_1
  doi: 10.1038/s41467-019-09735-4
– ident: e_1_2_10_32_1
  doi: 10.3109/15376516.2012.730558
– ident: e_1_2_10_20_1
  doi: 10.1016/j.tem.2016.07.002
– ident: e_1_2_10_30_1
  doi: 10.3390/nu14163384
– ident: e_1_2_10_35_1
  doi: 10.2337/diabetes.54.7.2206
– ident: e_1_2_10_27_1
  doi: 10.2174/157339908783502361
– ident: e_1_2_10_33_1
  doi: 10.1152/ajprenal.00184.2019
– ident: e_1_2_10_4_1
  doi: 10.1038/s41581-018-0018-2
– ident: e_1_2_10_1_1
  doi: 10.1038/ncpendmet0894
– ident: e_1_2_10_22_1
  doi: 10.1016/j.biopha.2018.10.041
– ident: e_1_2_10_9_1
  doi: 10.1038/s41419-021-03452-x
– ident: e_1_2_10_16_1
  doi: 10.1016/j.bbi.2017.06.018
– ident: e_1_2_10_11_1
  doi: 10.1016/j.molmet.2022.101470
– ident: e_1_2_10_6_1
  doi: 10.1007/s12020-021-02721-1
– ident: e_1_2_10_23_1
  doi: 10.3748/wjg.v26.i18.2187
– ident: e_1_2_10_34_1
  doi: 10.1007/s12011-014-0021-9
– ident: e_1_2_10_12_1
  doi: 10.1111/fcp.12232
SSID ssj0031243
Score 2.5156803
Snippet To investigate the underlying mechanism of Astragaloside IV (AS-IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology and...
ScopeTo investigate the underlying mechanism of Astragaloside IV (AS‐IV) in ameliorating diabetic nephropathy (DN) by regulating intestinal microbiota ecology...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage e2300734
SubjectTerms Diabetes
Diabetes mellitus
Diabetic nephropathy
Digestive system
Dysbacteriosis
Ecological effects
Fecal microflora
Ferroptosis
Gastrointestinal tract
Gut microbiota
Intestinal microflora
Intestine
Microbiomes
Microbiota
Microorganisms
Mucosa
Nephropathy
Permeability
Renal function
Transplantation
Title Astragaloside IV Mitigated Diabetic Nephropathy by Restructuring Intestinal Microflora and Ferroptosis
URI https://www.ncbi.nlm.nih.gov/pubmed/38389170
https://www.proquest.com/docview/3031009049
https://www.proquest.com/docview/3031658078
Volume 68
WOSCitedRecordID wos001169619900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1613-4133
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0031243
  issn: 1613-4125
  databaseCode: DRFUL
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fa9swEBZrOkZfxn7PW1c0GNtD8ObYsS09lnRhgyaMko68GUs5MUPrhCYdzX-_k2TJDjSwPezFGEu2Qd_n091Z-o6QD_rPSwpxGg5UbrJVcShyViIgJc9ylZWQKVNsIp9O2XzOfzQJ_bUpJ5DXNbu746v_CjVeQ7D11tl_gNs_FC_gOYKOR4Qdj38F_KlOXqDdX-pCnH2M7iaV0dFAz9Iuf6kkmraVLo-A3t9W-58XYGVk7ZZFnSTED1-7qRO9XE9hSG92bvXHcIN3bfDJ665TO3Eldvu10_Y3jFJaMblRE_JZ5_PtrYZ1XnlW-pz1DN8eztxcahK55t_Jr3a72qjZTDKCbroiHrbrtT6DNbHoQIQ4dSYdswkYCKGtGd5r061G7HWttHzrPR1x-FfXBkyMthmGn1E7t_kVh67pgBzGecpZjxyeXYwvz92snaCfkzhRzyj-svu6I_LIPWDXf9kTlBjnZPaEPG6iCnpq2fCUPID6GQnOKtjQj7SRfr2iU4fOc6J2WEK__6SeJdSxhHZYQsWW7rCEtiyhLUsosoR2WPKCXI6_zkbfwqbkRiiTONmEKpMYPzKAdMFlgieRiEQqBvki46CApZlQAvJooXBc1IDLtEwAAP10OeQLBPUl6dXLGl4TGkdScSGzUm92ToEJwdIFMCn5UA6iMg5I6AaykI0evS6LclVYJe240BgUHoOAfPL9V1aJZW_PY4dL0XyY6yLRGrgRx4A4IO99M9pS_YOsrGF5a_ugR45ec0BeWTz9qxz-b_a2vCVHLeGPSQ8hgXfkofy9qdY3J-Qgn7OThnV_AHOqnI4
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Astragaloside+IV+Mitigated+Diabetic+Nephropathy+by+Restructuring+Intestinal+Microflora+and+Ferroptosis&rft.jtitle=Molecular+nutrition+%26+food+research&rft.au=Lyu%2C+Xin&rft.au=Zhang%2C+Ting-Ting&rft.au=Ye%2C+Zhen&rft.au=Chen%2C+Ce&rft.date=2024-03-01&rft.eissn=1613-4133&rft.spage=e2300734&rft_id=info:doi/10.1002%2Fmnfr.202300734&rft_id=info%3Apmid%2F38389170&rft.externalDocID=38389170
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1613-4125&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1613-4125&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1613-4125&client=summon